Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
Status:
Completed
Trial end date:
2016-09-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of BG00012 (dimethyl fumarate)
on brain magnetic resonance imaging (MRI) lesions in pediatric participants with
relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are to
characterize the pharmacokinetics of BG00012 in pediatric participants with RRMS and to
evaluate the safety and tolerability of BG00012 in pediatric participants with RRMS.